Our publications

Kemp Z, Turnbull A, Yost S, Ruark E, Seal S, Warren-Perry M, Eccleston A, Strydom A, George A, Rahman N (2019). Cancer status is simpler and more effective than family history in determining BRCA testing eligibility (in preparation)

Mahamdallie S, Ruark E, Holt E, Poyastro-Pearson E, Renwick A, Strydom A, Seal S, and Rahman N. (2018). The ICR639 CPG NGS validation series: A resource to assess analytical sensitivity of cancer predisposition gene testing. Wellcome Open Research 2018, 3:68 (doi: 10.12688/wellcomeopenres.14594.1)

Mahamdallie S, Ruark E, Yost S, Ramsay E, Uddin I, Wylie H, Elliott A, Strydom A, Renwick A, Seal S, and Rahman N. (2017). The ICR96 exon CNV validation series: a resource for orthogonal assessment of exon CNV calling in NGS data. Wellcome Open Research 2017, 2:35 (doi: 10.12688/wellcomeopenres.11689.1)

Fowler A, Mahamdallie S, Ruark E, Seal S, Ramsay E, Clarke M, Uddin I, Wylie H, Strydom A, Lunter G, and Rahman N. (2016). Accurate clinical detection of exon copy number variants in a targeted NGS panel using DeCoN. Wellcome Open Research 2016, 1:20 (doi: 10.12688/wellcomeopenres.10069.1)

Percival N, George A, Gyertson J, Hamill M, Fernandes A, Davies E, Rahman N, and Banerjee S. (2016) The integration of BRCA testing into oncology clinics. British Journal of Nursing 25(12):690-4

Eccleston A, Bentley A, Dyer M, Strydom A, Vereecken W, George A, and Rahman N. (2016) A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer. Value in Health 20(4): 567-576

George A, Riddell D, Seal S, Talukdar S, Mahamdallie S, Ruark E, Cloke V, Slade I, Kemp Z, Gore M, Strydom A, Banerjee S, Hanson H, and Rahman N. (2016) Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients. Scientific Reports 6: 29506

Rahman, N. (2014) Realizing the promise of cancer predisposition genes. Nature 505:302-308.

Rahman, N. (2014) Mainstreaming genetic testing of cancer predisposition genes. Clinical Medicine 14(4):436-439

Slade I, Hanson H, George A, Kohut K, Strydom A, Wordsworth S, and Rahman N. (2016) A cost analysis of a cancer genetic service model in the UK. Journal of Community Genetics 7 (3): 185-194

Slade I, Riddell D, Turnbull C, Hanson H, and Rahman N for the MCG programme. (2015) Development of cancer genetic services in the UK: A national consultation. Genome Medicine 7:18.

Münz M, Ruark E, Renwick A, Ramsay E, Clarke M, Mahamdallie S, Cloke V, Seal S, Strydom A, Lunter G, and Rahman N. (2015) CSN and CAVA: variant annotation tools for rapid, robust next-generation sequencing analysis in the clinical setting. Genome Medicine 7:76.

[spacer height=”10px”]

Press releases and information packs

Mar 2015 – MCG Information Pack
Jan 2014 – ‘A new pathway for cancer gene testing successfully completes pilot’ – Information Pack
Jan 2014 – ‘A new pathway for cancer gene testing successfully completes pilot’ – Press Release
May 2013 – MCG Launch Press Release

[spacer height=”10px”]

Other resources

Nov 2015 – Cancer Predisposition Genes on the TruSight Cancer panel version 2
Jan 2015 – Would you have your genome sequenced? Let us know by completing our short survey
Jul 2014 – Wellcome Trust Centre for Human Genetics (WTCHG) High-Throughput Sequencing Tools
Jan 2013 – Methodology for selection of TruSight Cancer panel content
Jan 2013 – Cancer Predisposition Genes on the TruSight Cancer panel


To see what other people are saying about the MCG programme, see our In the News page.